Floatz logo

PURINOSTAT

Recurrent and Refractory Diffuse Large B-cell Lymphoma

Chengdu Zenitar Biomedical Technology Co., LtdSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Recurrent and Refractory Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
Purinostat Mesylate For
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3B

Same molecule, other indications

PURINOSTAT is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
53 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →